Summit Therapeutics (SMMT) to Release Earnings on Wednesday

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) is scheduled to be announcing its earnings results before the market opens on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. On average, analysts expect Summit Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Summit Therapeutics Price Performance

Shares of NASDAQ SMMT traded down $0.57 during mid-day trading on Thursday, hitting $19.46. 1,416,385 shares of the company's stock traded hands, compared to its average volume of 3,690,851. Summit Therapeutics has a 1 year low of $1.64 and a 1 year high of $33.89. The company's 50-day moving average is $18.90 and its two-hundred day moving average is $11.12. The company has a market capitalization of $14.10 billion, a P/E ratio of -84.61 and a beta of -0.97.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on SMMT shares. HC Wainwright restated a "buy" rating and set a $45.00 price objective on shares of Summit Therapeutics in a research report on Friday, October 4th. Citigroup lowered Summit Therapeutics from a "buy" rating to a "neutral" rating and increased their price target for the company from $19.00 to $23.00 in a report on Friday, September 27th. Finally, Stifel Nicolaus raised their price target on Summit Therapeutics from $25.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, September 25th.

Summit Therapeutics Company Profile

Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.